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Abstract
Antibodies named TcCRA “Trypanosoma cruzi Cross Reactive Antibodies” were detected
in 47% of blood donors from French population unexposed to the parasite. In order to evalu-
ate the passive or active transmissibility of TcCRA and further characterize its role and etiol-
ogy, we have conducted a study in a cohort of 47 patients who underwent allogeneic
Hematopoietic Stem Cell Transplantations (allo-HSCT). Donors and recipients were tested
for TcCRA prior to transplantation. Recipients were further tested during follow-up after
transplantation. Demographical, clinical and biological data were collected. Our primary
end-point was to assess the risk of TcCRA acquisition after transplantation. During this ini-
tial analysis, we observed no seroconversion in patients receiving cells from TcCRA nega-
tive donors (n = 23) but detected seroconversion in 4 out of 24 patients who received
hematopoietic stem cells from positive donors. Here, we are discussing possible scenarios
to explain TcCRA-immune status in recipient after transplantation.
Introduction
In the course of biomarker evaluation of a neglected disease (Chagas disease), we made a
remarkable observation of a highly prevalent antibody specificity in unexposed European
serum samples. These specific antibodies were named “Trypanosoma cruzi Cross Reactive
Antibodies” (TcCRA) to stress out the fact that they were induced by another antigen than the
one from T. cruzi, the causative agent of Chagas disease [1]. Focusing on opportunistic infec-
tion, we investigated TcCRA in patients undergoing allogeneic hematopoietic stem cells trans-
plantation (allo-HSCT) and explored its potential impact on transplantation outcomes.
While allo-HSCT represents a curative therapy for some hematological malignancies and
bone marrow failure states, relapse, graft-vs-host disease (GVHD) and infections continue to
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be major causes of morbidity and mortality following the engraftment [2–3]. We tested TcCRA
in blood samples from 47 adult recipients who underwent allo-HSCT as well as samples from
their donors. Under such conditions, serological antibody markers are typically observed either
by immune reconstitution, by blood derivatives passive transfer or by an immune response to
an infection. The main objective of the study was to identify possible TcCRA transmission or
acquisition in allo-HSCT recipients.
Patients and Methods
Study design, Patient population
We performed a prospective observational study. Patients and donors, all from Caucasian eth-
nicity, were recruited between January and June 2011. This prospective analysis was approved
by a Research institutional review board (CPP Sud-Est n° 2013/025) and all patients gave writ-
ten informed consent and assent as appropriate. All patients who were eligible for allo-HSCT
were included in the study. In this study, all blood samples were collected during patient’s stan-
dard care. Likewise, blood samples were drawn from the patients before starting the condition-
ing regimen, and then before hematopoietic stem cell infusion. During the early follow-up
(FU), testing for TcCRA determination was performed once per week during the first 12 weeks
following the transplantation. A later follow-up was performed for almost all patients at 3, 6, 9
and 12 months after transplantation. For donors, a blood sample was drawn at the time of
hematopoietic stem cell harvest. Data concerning age, sex, stem cell source, conditioning regi-
men, complications and infections after transplantation and follow-up were collected from the
allo-HSCT registry of the hematological department of Lyon.
Serological testing
TcCRA were measured in serum samples using an in-house ELISA test. The used method and
reagents are described in SABA et al 2013 [1]. All the collected samples were tested in duplicate
at least one time, if necessary twice, for validation. For some patients we tested serum for anti-
measles, anti-mumps and anti-CMV IgGs. Those tests were performed by using the corre-
sponding Enzygnost kit from SIEMENS.
Conditioning regimen and GVHD prophylaxis
The conventional conditioning regimen was mainly a combination of cyclophosphamide and
total body irradiation (TBI). The reduced-intensity conditioning regimen was mainly fludara-
bine combined with melphalan, cyclophosphamide, TBI and busulfan. The standard GVHD
prophylaxis after the transplantation consisted of cyclosporine A and methotrexate. Steroids
and/or Cyclosporine were used for the treatment of established acute or chronic GVHD.
Viral monitoring
Patient’s serological status of cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes sim-
plex virus (HSV), varicella zoster virus and toxoplasmosis were determined prior to transplan-
tation. All HSCT patients were tested by quantitative real-time PCR for EBV, CMV and HHV-
6 during the FU after transplantation. All patients received herpes prophylaxis i.v. valacyclovir.
CMV reactivation was treated with valgancyclovir and EBV reactivation with rituximab if test-
ing confirmed the viral activation.
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Statistical analysis
Statistical analysis was done using the SPSS ver.19 and Graph-pad prism 5. The two-tailed P
value was considered significant when<0.05. Mann-Whitney and Fisher exact tests were used
to calculate significance of continuous and categorical variables respectively.
Results
Patients’ characteristics
Forty seven recipients and their donors were included in the study. Among them there were
26 males and 21 females with a median age of 51 years (range: 35–58). TcCRA antibody were
followed during a median of 280 days. Diagnosis before transplantation was acute lympho-
blastic and myeloid leukemia (n = 19, n = 7), myelodisplesia (n = 7), non-Hodgkin’s lym-
phoma (n = 6) and other diagnosis including Hodgkin’s lymphoma (n = 1),
Myeloproliferative syndrome (n = 2), solid tumor (n = 1) and aplasia (n = 4). As HSC source,
22 patients have received peripheral blood cells, 23 bone marrow and 2 cord blood cells from
32 unrelated donors, HLA matched (n = 18) and HLA-mismatched (n = 14) and 15 siblings
donors. For ABO compatibility, 18 patients were compatible, 13 had minor incompatibility
and 16 had major incompatibility with their respective donor. As for conditioning regimens,
23 patients had a myeloablative and the remaining 24 patients had a reduced intensity condi-
tioning. Twenty patients died at different time points during the FU, 15 from transplantation
related complications and 5 from disease recurrence. Consequently, the numbers of available
samples at 3, 6, 9 and 12 months were respectively 41, 39, 31 and 27. The population was
divided in two groups according to the donors’ TcCRA status, all characteristics are shown in
Table 1.
To monitor TcCRA marker, we calculated the difference between the signals at baseline
(BL) and those measured at 3, 6, 9 and 12 months after transplantation (ΔTcCRA). Then we
compared the distribution of these values between the two groups (Fig 1). A difference
between groups became measurable at 9 months and significant at 12 months after the trans-
plantation. ΔTcCRA values showed a significant decrease in patients receiving cells from a
seronegative donor as compared to an increase in patients receiving cells from a seropositive
donor.
Longitudinal follow-up of TcCRA over one year after transplantation
Based on the observation of a late influence of the donor’s TcCRA-status, we focused our anal-
ysis on the 27 patients with available samples more than 9 months after transplantation (Fig 2).
We established a graphical representation of TcCRA signal evolution for each of these 27
patients and observed 4 different profiles depicted as IB1, IB2, IB3 and IB4 in Fig 3: The first
pattern is characterized by a general downward trend of TcCRA signals, in 8 patients with high
level of TcCRA (> 1 OD) at inclusion, a decrease in signal was observed after the conditioning
phase until the end of the follow-up (Fig 3, IB1). The second one, documented only in one
patient, TcCRA signal rises early after transplantation (47 days) and then stabilized until the
end of the follow-up period. The third profile is common for three patients, shows a late
increase in TcCRA signal, happening 200 days after transplantation. The fourth profile shows
no TcCRA variation in 15 patients (Fig 3, IB4). We have also observed transient peak of
TcCRA signal, we were able to correlate these peaks with a passive transfer of antibodies, car-
ried out mainly through i.v.Ig (intravenous immunoglobulin) injections (symbolized by black
arrows in Fig 3) and to a lesser extent through platelet and red blood cell transfusions.
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Influence of the donor’s serological status on the recipient’s post-graft
antibody repertoire
Interestingly, three patients with a late increase in TcCRA signals have had a TcCRA seroposi-
tive donor. This observation seems to be related with immune reconstitution after transplanta-
tion. To verify the hypothesis of a late immune reconstitution is of donors’ origin, we tested
patients for anti-measles and anti-mumps IgGs which are representative of infections widely
prevalent but unlikely to reactivate. We found that, over one year of follow-up, patients were
more likely to acquire their donor’s immune repertoire, as was apparent for patients IB5 and
Table 1. Patients’ characteristics.
Group donor TcCRA (-) Group donor TcCRA (+)
Recipient’s TcCRA BL (OD) 0.55 (0.29–0.81) 0.41 (0.20–0.64)
Recipient’s Age (years) 52 (35–57) 50 (38–58)
FU (days) 304 (152–367) 277 (104–368)
Total nb of cells in the graft (10^8 cells/Kg) 3.1 (1.6–9.8) 4.8 (2.3–13.1)
CD 34+ (10^6 cells/kg) 3.05 (1.1-.7) 4.5 (2.2–6)
CD 3+ (10^6 cells/kg) 39.6 (17.3–249) 51.8 (21.6–206)
Recipient’s gender (%) Female 11 (50) 11 (50)
Male 12 (48) 13 (52)
Deceased (%) No 13 (48) 14 (52)
Yes 10 (50) 10 (50)
HLA Match 13 (39) 20 (61)
Mismatch 10 (71) 4 (29)
Conditioning regimen (%) MA 13 (57) 10 (53)
RIC 10 (43) 13 (57)
ABO system Compatible 9 (50) 9 (50)
Minor incompatibility 8 (62) 5 (38)
Major incompatibility 7 (44) 9 (56)
Stem cells source (%) PB 11 (50) 11 (50)
BM 10 (44) 13 (56)
UC 2 (100) 0 (0)
Relation donor- recipient (%) Sibling 8 (53) 7 (47)
Unrelated 15 (47) 17 (53)
CMV serology recipient (%) IgG (-) 8 (57) 6 (43)
IgG (+) 15 (46) 18 (54)
EBV serology recipient (%) IgG (-) 0 0
IgG (+) 23 (48) 24 (50)
HSV1 serology recipient (%) IgG (-) 3 (43) 4 (57)
IgG (+) 20 (50) 20 (50)
VZV serology recipient (%) IgG (-) 1 0
IgG (+) 22 (48) 24 (52)
Toxoplasmosis serology recipient (%) IgG (-) 9 (69) 4 (31)
IgG (+) 14 (41) 20 (59)
Abbreviations: TcCRA = Trypanososma cruzi Cross Reactive Antibodies; HLA = Human Leucocyte Antigen; FU = Follow-up; BL = baseline;
CMV = cytomegalovirus; EBV = Epstein Barr virus; HSV1 = herpes simplex virus 1; VZV = varicella zoster virus; MA = myelo-ablative; RIC = reduced
intensity conditioning; PB = peripheral blood; BM = bone marrow; UC = umbilical cord.
doi:10.1371/journal.pone.0137240.t001
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IB3 (Fig 4). In contrast, patient IB2 showed an early conversion of TcCRA status that doesn’t
seem related to immune reconstitution as was shown for Measles and Mumps antibodies.
Early post-graft specific antibody forming ability
To further investigate the observation documented for the patient IB2, with an early increase
in TcCRA signal, we selected a third infectious agent (CMV) as a comparison basis, also largely
spread and strongly susceptible to reactivation in allo-HSCT patients. We measured anti-CMV
antibodies in recipients who underwent CMV reactivation (Fig 5). All tested patients were
CMV positive at inclusion. We found that only Patients who received cells from a CMV sero-
positive donor were able to specifically respond upon CMV reactivation. Fig 5 showed that
these patients had an increase in anti-CMV antibodies after the detection of CMV viremia
(symbolized by a black arrows) occurring within the first three months after transplantation.
However, this was not observed in the case of patients with a CMV seronegative donor who
Fig 1. Effect of donor’s TcCRA serological status on patients’ TcCRA-signal evolution. ΔTcCRA was
calculated at 3, 6, 9 and 12 months after graft to evaluate the gain or loss in TcCRA signal. The numbers of
available samples at 3, 6, 9 and 12 months were respectively 41, 39, 31 and 27.
doi:10.1371/journal.pone.0137240.g001
Fig 2. Classification of patients who survivedmore than 9months after the transplantation at baseline (BL) and at Follow up (FU) according to
their donor’s TcCRA serological status.
doi:10.1371/journal.pone.0137240.g002
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were not able to respond promptly after the reactivation and failed to produce specific anti-
CMV antibodies during the early post-transplantation periods.
Discussion
TcCRA are newly discovered antibodies of unknown origin, which might be the result of infec-
tion with an asymptomatic latent agent [1]. In the present study, we prospectively evaluated
the expression and dynamics of TcCRA in 47 pairs of adult HSCT donors/recipients. TcCRA
expression was shown to be stable over time in patients who had samples before transplanta-
tion (Fig 3, IB1). The loss or decline of immunity is common in the early phase following allo-
HSCT and generally contributes to patients’ susceptibility to infections [4]. This decline has
been well documented for immunity acquired in childhood through natural infections or vacci-
nation against mumps, rubella and poliomyelitis for example [5]. In our study, we found that
TcCRA-positive patients experienced a similar trend with at least 50% loss of reactivity 90 days
after transplantation (Data not shown). We also observed that transient peaks in TcCRA sig-
nals mainly correlate with exogenous immunoglobulins (IgGs) administration. The level of
passively transferred IgGs progressively decreased until complete clearance 30–60 days after
the initial injection. Taking into consideration that TcCRA is present in 47% of blood
Fig 3. TcCRA profile of four patients during the follow-up. The X axis represents time in days, where day zero designates the day of engraftment. The Y
axis represents TcCRA signals (O.D.) in recipients. Black arrows symbolize the dates of i.v.Ig injections while dotted black lines indicate transfusion periods
of other blood-products.
doi:10.1371/journal.pone.0137240.g003
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Fig 4. Serology profiles of three different patients including TcCRA, IgG anti-measles virus and IgG
anti-mumps virus. Donor’s serological status is presented for each patient as well. 0.2 (O.D.) represents the
cutoff for anti-measles and anti-mumps antibodies.
doi:10.1371/journal.pone.0137240.g004
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donations, we were not surprised to detect its presence in human blood derivatives such as
polyclonal therapeutic immnunoglobulins.
Our primary end-point was to assess the risk of TcCRA-immunity acquisition after the
recipient exposition to either a positive or a negative donor following allo-HSCT. We are
reporting here a TcCRA immunity acquisition in four patients after engraftment of cells from
positive donors, clearly unrelated to IgGs given intravenously. In 3/4 patients, TcCRA acquisi-
tion showed a similar profile to the acquisition of anti-measles and anti-mumps antibodies.
The antibody production observed in these patients beyond 6 month after allo-HSCT appeared
Fig 5. Patients’ antibodies anti-CMV profiling. The black arrows indicate the day of post-graft CMV reactivation (>100 copies/ml measured by PCR).
doi:10.1371/journal.pone.0137240.g005
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to reflect the transfer of immunity from donors’ cells after complete hematopoietic reconstitu-
tion [6]. This hypothesis is built on four pieces of evidence: “1” the antibodies that were
induced in recipients after allo-HSCT matched the donors’ immune repertoire, “2” when
donors were negative, recipients were found to be negative, including recipients who were posi-
tive at base-line, “3” recipients who developed serum IgG titers to measles and mumps were
unlikely to be “environmentally re-immunized”, “4” passive antibodies transferred through
administered blood derivatives did not influence antibody titers 6 months after transplantation.
To our view point, evidences mentioned above were not sufficient to explain why the TcCRA
profile for patient IB2 was different (Fig 3). Interestingly, in this case, the donor TcCRA signal
was the highest amongst all donors. The early development and the consequent persistence of
this immune response were particularly remarkable. The levels of detected antibodies suggested
a main role of specific B cells activation upon specific stimulus. To challenge this idea, we mea-
sured anti-CMV antibodies in patients who underwent CMV reactivation. Remarkably, only
recipients with CMV seropositive donors were capable to respond quickly after reactivation. It
doesn’t seems plausible that the detected anti-CMV antibodies resulted from the persistence of
differentiated host B cells, because it would also be observed in patients receiving cells from
CMV-seronegative donors (Fig 4). It was evident that anti-CMV antibodies response was
detected before complete hematopoietic engraftment which usually takes from 6 months up to
2 years [7–8]. Therefore, the adaptive transfer of primed immune cells from the donor to the
recipient appeared to be a more suitable scenario. Actually, the adaptive transfer of immuno-
competent cells routinely occurs during allo-HSCT [9]. This was reported in publications on
the effectiveness of vaccination after HSCT [5–10], as well as through cancer therapy where
immunized donor against tumor specific antigen might increase the recipient anti-cancer
response after HSCT [11–12].
The early rise in TcCRA signal in patient IB2 suggested a possible stimulation of donor’s
primed B-cells by the infectious agent inducing TcCRA. Being TcCRA-seronegative at inclu-
sion, it was unlikely that the agent was present in the host before allo-HSCT. It could therefore
derive either concomitantly with the graft or from an external source like transfusion or envi-
ronmental exposure. The last possibility was however unlikely to explain the seroconversion in
patient IB2, because of its occurrence at the period of time after transplantation when patients
were carefully isolated from the outside world. Moreover, the risk of transfusion related infec-
tion was highly minimized by the use of leuco-reduced products [13]. Given the high TcCRA
level of the donor and the fact that latent viruses are frequently transmitted via the transplanted
cells [14], we couldn’t unacknowledged the possibility of agent transmission via donor cells, at
least for this specific case.
In conclusion, this study has undoubtedly put forward our hypothesis of the implication of
an unknown, probably latent, asymptomatic virus responsible of TcCRA induction transmitted
possibly by blood cell. This agent may be part of the uncharacterized viruses that constitute
15% of healthy individuals’ blood virome as it was proposed by Popgeorgiev N et al. in their
work on Marseillevirus [15–16]. Our data showed the need to pursue research on the composi-
tion of blood derived products used in allo-HSCT setting that may have a clinical significance.
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